BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38610786)

  • 1. Traditional Clinicopathological Biomarkers Still Determine Disease-Free and Overall Survival in Invasive Breast Cancer Patients: A Pilot Study.
    Wrzeszcz K; Kwiatkowska K; Rhone P; Formanowicz D; Kruszewski S; Ruszkowska-Ciastek B
    J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610786
    [No Abstract]   [Full Text] [Related]  

  • 2. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
    El-Gendi SM; Mostafa MF
    Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
    Stavridi F; Kalogeras KT; Pliarchopoulou K; Wirtz RM; Alexopoulou Z; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2016; 11(10):e0164013. PubMed ID: 27695115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():831848. PubMed ID: 35320931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity in
    Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
    Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinicopathological Factors Associated with Disease Progression in Luminal A Breast Cancer and Characteristics of Metastasis: A Retrospective Study from A Single Center in China.
    Ye J; Wang W; Xin L; Owen S; Xu L; Duan X; Cheng Y; Zhang H; Zhang S; Li T; Liu Y
    Anticancer Res; 2017 Aug; 37(8):4549-4556. PubMed ID: 28739751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
    Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of extranodal extension in sentinel lymph node positive breast cancer.
    Yang X; Ma X; Yang W; Shui R
    Sci Rep; 2020 Sep; 10(1):14684. PubMed ID: 32895434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of extranodal extension in axillary lymph node-positive breast cancer.
    Ma X; Yang X; Yang W; Shui R
    Sci Rep; 2021 May; 11(1):9534. PubMed ID: 33953240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study.
    Zheng Y; Wu C; Yan H; Chen S
    Clin Chim Acta; 2020 Jul; 506():110-121. PubMed ID: 32156604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study.
    Liu G; Xing Z; Guo C; Dai Q; Cheng H; Wang X; Tang Y; Wang Y
    Front Oncol; 2023; 13():1217869. PubMed ID: 37601676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
    Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
    Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
    Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes.
    Barbara RC; Piotr R; Kornel B; Elżbieta Z; Danuta R; Eduardo N
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.